CEO/CFO cluster buys at RLMD are the strongest insider signal in the dataset per academic literature. With the stock near $4.10-4.25 and institutional holders like Jupiter Topco ($77M) already in, this suggests management sees material upside. Monitor for upcoming pipeline catalysts or partnership announcements that could explain the concentrated buying.
RLMD drugs
RLMD drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 11 $4.52entry
- T+1 · 2mo ago −1.77%α −1.32% · $4.44
- T+5 · 2mo ago −8.85%α −8.63% · $4.12
- T+20 · 6w ago −25.00%α −26.87% · $3.39
- T+46 · todayOpen
- T+60 · in 20d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
RLMD CEO Sergio Traversa and CFO Maged Shenouda collectively purchased $1.67M of stock in open-market transactions over two days (Sep 9-10), with the CEO buying 200K shares and the CFO buying 200K shares. This is a strong cluster buy signal from both top C-suite executives, representing approximately 0.38% of the company's $434M market cap, which is a modest but notable insider conviction signal for a clinical-stage biotech.
Key Financial Metrics
Key Facts
- CEO Sergio Traversa purchased 200,000 shares total ($828K) on Sep 9-10 at $4.10-$4.18
- CFO Maged Shenouda purchased 200,000 shares total ($844K) on Sep 9-10 at $4.20-$4.25
- Combined insider purchases of $1.67M represent ~0.38% of RLMD's $434M market cap
- Both executives bought in open-market transactions, not grants or exercises
- Recent 30-day insider activity shows 4 buys totaling $1.7M, consistent with this cluster
- Institutional ownership shows Jupiter Topco ($77M), BlackRock ($51M), Adage Capital ($33M) as top holders
Financial Impact
$1.67M in insider purchases, 0.38% of market cap, modest but high-signal given C-suite cluster
Risk Factors
- Clinical-stage biotech with no approved products, binary pipeline risk remains
- $1.67M is only 0.38% of market cap, so signal strength depends on insider conviction rather than dollar magnitude
- No specific catalyst disclosed, buying could be valuation-driven rather than event-driven
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-RLMD-1789127045139 |
Track record
11 reports on RLMD
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G/A Bearish 5/10 Entry $3.54 Now $3.61 −1.98% settles Dec 15
- Nov 16, 2026today 8-K Neutral 3/10 Entry $4.16 Now $3.61 −13.23% settles Dec 15
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $4.21 Now $3.61 −14.25% settles Dec 14
- Sep 11, 20269w ago Insider Cluster Bullish 6/10 Viewing Entry $4.52 to $3.39 Now $3.61 −20.13% ▼ −25.00% −26.87% vs SPY
- May 13, 202626w ago S-3ASR Bearish 6/10 Entry $7.42 to $6.65 Now $3.61 +51.35% ▲ +10.38% +9.52% vs SPY
- May 12, 202626w ago 8-K Neutral 4/10 Entry $7.49 to $6.52 Now $3.61 −51.80% ▼ −12.95% −12.34% vs SPY
- Apr 17, 202630w ago DEFA14A Neutral 3/10 Entry $7.37 to $6.34 Now $3.61 −51.02% ▼ −13.98% −18.18% vs SPY
- Apr 3, 202632w ago S-3 Neutral 3/10 Entry $6.90 to $7.41 Now $3.61 −47.68% ▲ +7.39% −1.59% vs SPY
- Mar 19, 202634w ago Press Release Bullish 8/10 Entry $6.07 to $7.37 Now $3.61 −40.53% ▲ +21.42% +12.10% vs SPY
- Mar 12, 202635w ago Press Release Neutral 3/10 Entry $6.15 to $7.29 Now $3.61 −41.30% ▲ +18.54% +16.56% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers